we’ve built a broad structural heart portfolio across the spectrum to restore health and improve quality of life for patients with structural heart disease.
Abbott offers a broad portfolio of structural heart solutions for an array of conditions. We invest in creating innovative technologies and advancing science, with the ultimate goal of helping patients achieve better health and improved quality of life. With our legacy of innovation, product diversity, safety, and performance, Abbott is your partner for structural heart therapies.
Some of the ways Abbott demonstrates its leadership in the industry include:
- Established leader in transcatheter edge-to-edge repair (TEER)* with MitraClipTM1
- Offering among the broadest occluder portfolios, with 20+ years of leadership1
- Demonstrating exceptional hemodynamics with tissue valves, and an impressive 40-year legacy with mechanical valves
- Providing outstanding & competitive clinical outcomes physicians expect from the latest generation TAVI system
*TEER is also referred to as TMVr (transcatheter mitral valve repair)
Established leader in
transcatheter mitral valve repair
with MitraClipTM 1
years of leadership
We offer a broad portfolio
with PFO, LAA, PDA, septal,
and muscular VSD occluders
We have an impressive 40-year legacy with mechanical valves and have demonstrated exceptional hemodynamics with tissue valves
TRANSCATHETER VALVE SOLUTIONS
BUILT TO HELP
Our minimally invasive transcatheter mitral valve repair therapy delivers excellent outcomes, and are particularly valuable for select patients who are not eligible for surgical valve repair.
SURGICAL VALVE SOLUTIONS
DESIGNED TO REBUILD HEALTHIER HEARTS
Our comprehensive surgical valve portfolio delivers long-term durability and performance, exceptional hemodynamics, and streamlined implantability.
BUILT FOR THE AGES.
Our occluders are built to close an opening in patients’ hearts—saving and restoring lives by providing closure with confidence.
Learn about our
Structural Heart Portfolio
Explore the interactive heart model below to learn more about our products and solutions across the structural heart spectrum.
Mitral RegurgitationA condition in which the mitral valve does not close completely during the contraction of the left ventricle, causing blood to leak backward into the left atrium.
MitraClipTM TherapyMitraClipTM Therapy is a minimally invasive TMVr therapy that delivers a treatment option for select patients with mitral regurgitation who would otherwise go untreated.**TMVr is also referred to as TEER (Transcatheter edge-to-edge repair)Learn More
EpicTM Plus Mitral Stented Tissue ValveThe EpicTM Plus Mitral stented tissue valve is intended for patients requiring replacement of a diseased, damaged, or malfunctioning native or prosthetic mitral heart valve.Learn More
Aortic StenosisA narrowing of the aortic valve, which reduces or blocks blood flow from the left ventricle to the aorta.
PorticoTM ValveThe PorticoTM with FlexNavTM TAVI system is a minimally invasive treatment for patients with aortic valve stenosis.Learn More
EpicTM Plus Supra Stented Tissue ValveThe EpicTM Plus Supra stented tissue valve is intended for patients requiring replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic heart valve.Learn More
RegentTM MHVThe RegentTM mechanical heart valve is intended for patients requiring replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic valve.Learn More
TrifectaTM GT ValveThe TrifectaTM Valve with GlideTM Technology (GT) is intended for patients requiring replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic heart valve.Learn More
Stroke Risk ReductionLeft atrial appendage (LAA) closure reduces the risk of stroke in non-valvular AF patient. Percutaneous closure of the patent foramen ovale (PFO) to prevent thrombus formation.
AmplatzerTM AmuletTM LAA OccluderA percutaneous transcatheter device intended to reduce the risk of thrombus embolization from the left atrial appendage (LAA) in suitable patients with nonvalvular atrial fibrillation.Learn More
AmplatzerTM TalismanTM PFO OccluderDesigned for patent foramen ovale (PFO) closure, the AmplatzerTM TalismanTM PFO occluder reduces the risk of recurrent ischemic stroke.Learn More
Congenital defectsCongenital heart defects can involve the walls of the heart, the heart valves, and arteries and veins near the heart, disrupting normal blood flow.
AmplatzerTM Septal OccluderA percutaneous transcatheter device for patients requiring atrial septal defect (ASD) closure.Learn More
AmplatzerTM VSD OccluderVentricular septal defects (VSDs) are the most common congenital heart defect, and AmplatzerTM Muscular VSD Occluders provide minimally invasive treatment options.Learn More
MAT-2004253 v7.0 | Item approved for U.S. use only.